KR20210099027A - 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 - Google Patents

항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 Download PDF

Info

Publication number
KR20210099027A
KR20210099027A KR1020217019296A KR20217019296A KR20210099027A KR 20210099027 A KR20210099027 A KR 20210099027A KR 1020217019296 A KR1020217019296 A KR 1020217019296A KR 20217019296 A KR20217019296 A KR 20217019296A KR 20210099027 A KR20210099027 A KR 20210099027A
Authority
KR
South Korea
Prior art keywords
ser
seq
antibody
val
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217019296A
Other languages
English (en)
Korean (ko)
Inventor
청 리아오
자화 장
주펑 수
리안샨 장
유안 린
칸 린
수에밍 치안
페이 텅
Original Assignee
지앙수 헨그루이 메디슨 컴퍼니 리미티드
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 메디슨 컴퍼니 리미티드, 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 메디슨 컴퍼니 리미티드
Publication of KR20210099027A publication Critical patent/KR20210099027A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
KR1020217019296A 2018-11-30 2019-11-29 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 Ceased KR20210099027A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811448228.1 2018-11-30
CN201811448228 2018-11-30
PCT/CN2019/121941 WO2020108611A1 (zh) 2018-11-30 2019-11-29 抗cd40抗体、其抗原结合片段及其医药用途

Publications (1)

Publication Number Publication Date
KR20210099027A true KR20210099027A (ko) 2021-08-11

Family

ID=70851924

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217019296A Ceased KR20210099027A (ko) 2018-11-30 2019-11-29 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도

Country Status (11)

Country Link
US (1) US20220025060A1 (https=)
EP (1) EP3892634A4 (https=)
JP (1) JP2022509156A (https=)
KR (1) KR20210099027A (https=)
CN (1) CN112969714B (https=)
AU (1) AU2019389354A1 (https=)
BR (1) BR112021009835A2 (https=)
CA (1) CA3120793A1 (https=)
MX (1) MX2021005823A (https=)
TW (1) TW202039558A (https=)
WO (1) WO2020108611A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022332499A1 (en) 2021-08-24 2024-03-21 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fap/cd40 binding molecule and medicinal use thereof
EP4482873A1 (en) * 2022-02-21 2025-01-01 Concept to Medicine Biotech Co., Ltd. Tumor antigen-dependent cd40 agonist antibodies
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
WO2023186111A1 (zh) * 2022-04-02 2023-10-05 和铂医药(上海)有限责任公司 一种靶向cd40的抗原结合蛋白及其制备和应用
KR20250019077A (ko) 2022-05-31 2025-02-07 퓨쳐진 바이오파머쓰티컬 (베이징) 코., 엘티디. 항-cd40 항체 및 항-pd-l1×cd40 이중특이성 항체 및 이의 용도
CN117229396A (zh) * 2022-06-06 2023-12-15 普米斯生物技术(珠海)有限公司 抗cd40抗体及其用途
WO2024076969A1 (en) * 2022-10-04 2024-04-11 Memorial Sloan-Kettering Cancer Center Anti-cd40 antibodies and uses thereof
TW202432588A (zh) 2022-12-28 2024-08-16 大陸商蘇州盛迪亞生物醫藥有限公司 一種cd40結合分子的組成物及醫藥用途
WO2024155778A2 (en) * 2023-01-18 2024-07-25 Michael Kaleko Ph-selective antibody-based checkpoint inhibitors for conditional antibody-dependent cellular cytotoxicity
KR20250153216A (ko) 2023-02-24 2025-10-24 상하이 맙젠 바이오텍 리미티드 Fap/cd40 결합 분자의 약학적 조성물 및 이의 의약적 용도
TW202436358A (zh) 2023-03-01 2024-09-16 大陸商江蘇恆瑞醫藥股份有限公司 Ｆａｐ／４－１ｂｂ／ｃｄ４０結合分子及其醫藥用途
CN117924488A (zh) * 2023-12-13 2024-04-26 合肥天港免疫药物有限公司 阻断性cd40抗体及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
EP1322383B9 (en) 2000-10-02 2006-09-06 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CN1922316B (zh) * 2003-12-25 2011-03-23 协和发酵麒麟株式会社 抗cd40抗体突变体
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
US20070292439A1 (en) * 2004-04-27 2007-12-20 Novartis Vaccines And Diagnostics, Inc. Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP2471813B1 (en) 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
US8303955B2 (en) 2005-05-26 2012-11-06 Seattle Genetics, Inc. Humanized anti-CD40 antibodies and their methods of use
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
EP2176298B1 (en) 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
HUE049849T2 (hu) * 2010-03-31 2020-10-28 Boehringer Ingelheim Int Anti-CD40 antitestek
EP2566514A4 (en) * 2010-05-03 2013-11-27 Abbvie Inc METHODS OF INHIBITING FIBROSIS WITH ANTI-PAI-1 ANTIBODIES
HUE038848T2 (hu) * 2011-04-21 2018-11-28 Bristol Myers Squibb Co CD40-antagonista antitest polipeptidek
ES2709654T3 (es) * 2011-04-29 2019-04-17 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
KR102270618B1 (ko) 2012-10-30 2021-06-30 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
JP6594855B2 (ja) 2013-03-15 2019-10-23 ゼンコア インコーポレイテッド ヘテロ二量体タンパク質
WO2015009853A1 (en) 2013-07-16 2015-01-22 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
GB201322583D0 (en) * 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
CA2957146A1 (en) * 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
AU2016249981B2 (en) * 2015-04-13 2022-02-17 Five Prime Therapeutics, Inc. Combination therapy for cancer
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
BR112017027549A2 (pt) * 2015-06-29 2018-09-11 Bristol-Myers Squibb Company anticorpo para cd40
CN107922500A (zh) * 2015-06-29 2018-04-17 洛克菲勒大学 具有增强的激动剂活性的抗cd40抗体
BR112018004296B1 (pt) 2015-09-04 2020-05-05 Primatope Therapeutics Inc anticorpos anti-cd40 humanizados e usos dos mesmos
CN106957366B (zh) * 2016-01-12 2022-02-01 上海昀怡健康科技发展有限公司 一种C5aR抗体及其制备方法和应用
TWI761348B (zh) * 2016-05-27 2022-04-21 美商艾伯維生物醫療股份有限公司 抗cd40抗體及其用途
AU2017310027A1 (en) * 2016-08-12 2019-01-31 Merck Patent Gmbh Combination therapy for cancer
MX2019011635A (es) * 2017-03-30 2020-01-20 Jiangsu Hengrui Medicine Co Método para la preparación de conjugados anticuerpo-fármaco.
AU2018278051A1 (en) * 2017-06-01 2020-01-30 Jiangsu Hengrui Medicine Co., Ltd. Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof

Also Published As

Publication number Publication date
CN112969714B (zh) 2022-11-22
TW202039558A (zh) 2020-11-01
WO2020108611A1 (zh) 2020-06-04
CN112969714A (zh) 2021-06-15
AU2019389354A1 (en) 2021-07-15
MX2021005823A (es) 2021-07-15
CA3120793A1 (en) 2020-06-04
JP2022509156A (ja) 2022-01-20
EP3892634A4 (en) 2022-11-16
US20220025060A1 (en) 2022-01-27
EP3892634A1 (en) 2021-10-13
BR112021009835A2 (pt) 2021-08-17

Similar Documents

Publication Publication Date Title
CN112969714B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN110267989B (zh) 抗cd40抗体、其抗原结合片段及其医药用途
JP6983371B2 (ja) 抗ｐｄ−ｌ１抗体、その抗原結合フラグメントおよびその医療用途
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
KR20210137477A (ko) 이중기능성 융합 단백질 및 그것의 제약학적 용도
JP7627258B2 (ja) 抗ｂｃｍａ抗体、その抗原結合断片、及びそれらの医療用途
JP2021519088A (ja) 抗ｃｄ２７抗体、その抗原結合フラグメント及びその医学的使用
TWI685504B (zh) 抗gitr抗體、其抗原結合片段及其醫藥用途
JP2019531732A (ja) 抗ｃｄ２７抗体、その抗原結合性フラグメント、およびそのものの医学的使用
RU2779128C2 (ru) Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение
HK40051457A (en) Anti-cd40 antibody, antigen binding fragment and pharmaceutical use thereof
WO2025113640A1 (zh) 结合lilrb1/2或pd1-lilrb1/2的抗体及其用途
KR20240046557A (ko) 항-b7-h4 항체 및 이의 제조 방법과 용도
CN119285769A (zh) 多特异性抗体及其医药用途
HK40013344A (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601